Expressions of interest now open for The Bridge Program
18th Apr 17
The Bridge Program will see 100 participants from all parts of Australia participate, receiving training in the scientific, legal, financial, clinical, and regulatory and reimbursement disciplines that contribute to the commercialisation of medicines.
The program was designed to address the lack of commercialisation skills and business acumen which is a common theme across the innovation ecosystem not only among researchers and life science entrepreneurs.
What makes this program unique is its integration with venture capital and global pharmaceutical networks - it involves a consortium of 14 pharmaceutical companies, the Medical Research Commercialisation Fund and AVCAL as well as other universities and industry associations.
The industry will match $540,000 of funding to deliver the initiative, which will cover:
- Protecting intellectual property
- Structuring biotech financing deals
- Designing clinical trials to shorten regulatory approval processes
- Enhancing reimbursement returns
The Bridge Program is being run by Queensland University of Technology.
Closing date: 28 April 2017.
Author: Rick Baker, Co-founder, Blackbird Ventures.
Originally published on Blackbird Ventures' blog on 6 March 2017.
Author: Yasser El-Ansary, Chief Executive, AVCAL